NASDAQ:RGEN - Repligen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $100.71 +0.81 (+0.81 %) (As of 01/21/2020 04:25 AM ET) Add Compare Today's Range$99.66Now: $100.71▼$100.9150-Day Range$87.82MA: $93.25▼$100.7152-Week Range$52.87Now: $100.71▼$101.00Volume254,459 shsAverage Volume276,576 shsMarket Capitalization$5.24 billionP/E Ratio205.53Dividend YieldN/ABeta1.12 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:RGEN Previous Symbol CUSIP75991610 CIK730272 Webhttp://www.repligen.com/ Phone781-250-0111Debt Debt-to-Equity Ratio0.25 Current Ratio16.03 Quick Ratio14.70Price-To-Earnings Trailing P/E Ratio205.53 Forward P/E Ratio97.78 P/E Growth4.6 Sales & Book Value Annual Sales$194.03 million Price / Sales27.02 Cash Flow$1.12 per share Price / Cash Flow89.94 Book Value$14.03 per share Price / Book7.18Profitability EPS (Most Recent Fiscal Year)$0.73 Net Income$16.62 million Net Margins9.28% Return on Equity6.50% Return on Assets5.12%Miscellaneous Employees548 Outstanding Shares52,060,000Market Cap$5.24 billion Next Earnings Date2/20/2020 (Estimated) OptionableOptionable Receive RGEN News and Ratings via Email Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RGEN Rates by TradingView Repligen (NASDAQ:RGEN) Frequently Asked Questions What is Repligen's stock symbol? Repligen trades on the NASDAQ under the ticker symbol "RGEN." How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) announced its earnings results on Thursday, October, 31st. The biotechnology company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.07. The biotechnology company had revenue of $69.45 million for the quarter, compared to analyst estimates of $66.10 million. Repligen had a return on equity of 6.50% and a net margin of 9.28%. The company's quarterly revenue was up 40.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.20 EPS. View Repligen's Earnings History. When is Repligen's next earnings date? Repligen is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Repligen. What guidance has Repligen issued on next quarter's earnings? Repligen updated its FY19 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $1.00-1.04 for the period, compared to the Thomson Reuters consensus estimate of $0.97. The company issued revenue guidance of $267-270 million, compared to the consensus revenue estimate of $266.06 million. What price target have analysts set for RGEN? 7 brokers have issued twelve-month price objectives for Repligen's stock. Their forecasts range from $100.00 to $110.00. On average, they expect Repligen's share price to reach $106.14 in the next twelve months. This suggests a possible upside of 5.4% from the stock's current price. View Analyst Price Targets for Repligen. What is the consensus analysts' recommendation for Repligen? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen. What are Wall Street analysts saying about Repligen stock? Here are some recent quotes from research analysts about Repligen stock: 1. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share." (8/12/2019) 2. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (8/7/2019) Has Repligen been receiving favorable news coverage? Media headlines about RGEN stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Repligen earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Repligen. Are investors shorting Repligen? Repligen saw a drop in short interest in December. As of December 31st, there was short interest totalling 2,420,000 shares, a drop of 29.4% from the December 15th total of 3,430,000 shares. Based on an average trading volume of 397,600 shares, the days-to-cover ratio is presently 6.1 days. Currently, 5.1% of the company's shares are short sold. View Repligen's Current Options Chain. Who are some of Repligen's key competitors? Some companies that are related to Repligen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Veeva Systems (VEEV), Xilinx (XLNX), salesforce.com (CRM), NextEra Energy (NEE), AT&T (T), Corcept Therapeutics (CORT) and Fortinet (FTNT). Who are Repligen's key executives? Repligen's management team includes the folowing people: Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)Mr. Jon K. Snodgres, CFO & Sec. (Age 53)Mr. Steve Curran, VP of Global OperationsMs. Sondra S. Newman, Sr. Director of Investor RelationsMr. Stephen Tingley, VP of Sales Who are Repligen's major shareholders? Repligen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Summit Creek Advisors LLC (0.16%), Assenagon Asset Management S.A. (0.02%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.01%), NewSquare Capital LLC (0.01%) and Allred Capital Management LLC (0.00%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen. Which institutional investors are selling Repligen stock? RGEN stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Summit Creek Advisors LLC. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes and Ralf Kuriyel. View Insider Buying and Selling for Repligen. Which institutional investors are buying Repligen stock? RGEN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., NewSquare Capital LLC, Allred Capital Management LLC, Lenox Wealth Advisors LLC, Louisiana State Employees Retirement System and Nisa Investment Advisors LLC. View Insider Buying and Selling for Repligen. How do I buy shares of Repligen? Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Repligen's stock price today? One share of RGEN stock can currently be purchased for approximately $100.71. How big of a company is Repligen? Repligen has a market capitalization of $5.24 billion and generates $194.03 million in revenue each year. The biotechnology company earns $16.62 million in net income (profit) each year or $0.73 on an earnings per share basis. Repligen employs 548 workers across the globe.View Additional Information About Repligen. What is Repligen's official website? The official website for Repligen is http://www.repligen.com/. How can I contact Repligen? Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The biotechnology company can be reached via phone at 781-250-0111 or via email at [email protected] MarketBeat Community Rating for Repligen (NASDAQ RGEN)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 312 (Vote Outperform)Underperform Votes: 293 (Vote Underperform)Total Votes: 605MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2020 by MarketBeat.com StaffFeatured Article: Why is the ex-dividend date different from the record date?
